Navigation Links
Skinvisible Appoints New Vice President of Business Development & Marketing

Strategic Plan for Invisicare Strengthens

LAS VEGAS, June 11 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that brings unique therapeutic and marketing benefits to topically applied products, announces a new executive appointment. Doreen McMorran will serve as Vice President of Business Development and Marketing, performing an integral role as the Company continues to grow in terms of new licensees, new products, new alliances as well as expansion into areas outside of dermatology.



Ms. McMorran will focus on driving business growth through new licensee acquisition for Skinvisible's formulated products and technology. She will contribute to the on-going strategic direction of the Company and will be charged with identifying and growing the Company's business opportunities. The goal is to identify new revenue streams through the penetration of markets complementary and additional to the Company's prime market of dermatology and to enhance the global reach of the Company.

"We have expanded our sales and marketing efforts in order to maintain our strategic business development momentum on a global scale," stated Mr. Terry Howlett, President and CEO of Skinvisible. "With Ms. McMorran's contacts in the dermatology industry and having her drive our strategic sales and marketing efforts, we are confident that she will successfully lead a focused and strategic sales effort that meets our long term growth objectives. We are excited to have Ms. McMorran on board as we continue to position Invisicare as the #1 choice for companies seeking enhanced features for their products and critical product life cycle management."

Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last six years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few, providing medical education for physicians and consumers about dermatology conditions, products and treatments. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

About Invisicare(R)

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See:

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See:

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154


SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Signs Licensing Agreement for Two Acne Formulations
2. Skinvisible Appoints New Board Member
3. Skinvisible Announces Licensing Agreement for Adapalene
4. Skinvisible Signs Marketing Agreement for India
5. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
6. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
7. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
8. amfAR Appoints Dr. Annette Sohn as Vice President of Global Initiatives
9. Disc Motion Technologies Appoints Industry Veteran as New CEO
10. Setaram Inc. Appoints New CEO/VP
11. VA Secretary Appoints Panel of National Suicide Experts
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , ... added Chris Hafey and Claude Hooton to its board of directors. The announcement ... America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from ...
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... With possible savings of up to 20% off orders $80 or more to free gifts ... every few hours. , As a competitive e-commerce website for skin care and cosmetic needs, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology: